Report cover image

Global Myelodysplastic Syndrome Drugs Market Size study, by Drug Type (Hypomethylating, Immune Therapy, Anti-anaemics), Route of Administration (Oral, Parenteral), Medication (Branded, Generic), Cancer Type, Age Group, End-user, and Regional Forecasts 202

Publisher Bizwit Research & Consulting
Published May 25, 2025
Length 285 Pages
SKU # BIZW20048182

Description

The Global Myelodysplastic Syndrome (MDS) Drugs Market is valued at approximately USD 2.8 billion in 2023 and is expected to register a robust compound annual growth rate of more than 8.00% over the forecast period 2024 to 2032. Myelodysplastic syndromes, a group of heterogeneous bone marrow disorders, are marked by ineffective hematopoiesis, leading to severe cytopenias and, in many cases, progression to acute myeloid leukemia (AML). As the clinical complexity of MDS continues to challenge hematologists globally, therapeutic developments have advanced significantly, shifting from generic supportive care to targeted disease-modifying regimens. Modern treatment strategies are increasingly focused on delaying disease progression, improving transfusion independence, and extending overall survival—especially in higher-risk MDS subtypes. Innovations in hypomethylating agents and the integration of immunotherapy protocols are shaping a more personalized and responsive market landscape.

The market's expansion is being driven by a confluence of scientific innovation, rising disease prevalence, and increasing demand for more tolerable and efficacious therapies. The aging global population—particularly in high-income nations—has escalated the incidence of MDS, while improved diagnostic criteria and awareness are contributing to earlier and more accurate patient identification. Biopharmaceutical companies are pushing forward new drug approvals and pipeline therapies, with hypomethylating agents like azacitidine and decitabine remaining foundational in first-line treatment. Furthermore, increasing focus on oral formulations and biosimilar development is opening doors for improved patient compliance and healthcare cost containment. Emerging therapeutic areas such as targeted immune therapies and the repositioning of anti-anaemic agents are also contributing significantly to market dynamism.

Nevertheless, several market challenges persist. Treatment-resistant disease and adverse effects from prolonged use of hypomethylating agents present major clinical hurdles. The high cost of branded therapies and the limited access to novel drugs in developing regions further constrain universal adoption. Additionally, regulatory complexities around orphan drug approvals and the intricate nature of conducting large-scale MDS trials can prolong product launches. That said, the rising tide of research into combination therapies, expansion of next-gen sequencing (NGS) tools for patient stratification, and the development of low-intensity regimens for elderly or frail patients signal promising future opportunities.

Geographically, North America commands the largest share of the MDS drugs market, attributed to its cutting-edge healthcare infrastructure, supportive reimbursement policies, and strong presence of industry leaders and clinical trial networks. The United States, in particular, is at the forefront with a high concentration of research activity and early adoption of breakthrough therapies. Europe trails closely, bolstered by well-structured national cancer programs and universal access to hematologic treatments in countries such as Germany, France, and the UK. Meanwhile, the Asia Pacific region is projected to exhibit the highest growth during the forecast timeline, driven by increasing healthcare investments, rising geriatric population, and enhanced access to hematology services in emerging economies like India and China. Latin America and the Middle East & Africa are also witnessing gradual improvement, supported by global health initiatives and public-private partnerships to enhance oncology treatment infrastructure.

Major market player included in this report are:
• Celgene Corporation (a Bristol-Myers Squibb Company)
• Novartis AG
• Otsuka Holdings Co., Ltd.
• Takeda Pharmaceutical Company Limited
• Pfizer Inc.
• Johnson & Johnson
• Merck & Co., Inc.
• Sanofi S.A.
• Teva Pharmaceutical Industries Ltd.
• Amgen Inc.
• F. Hoffmann-La Roche Ltd
• GlaxoSmithKline plc
• AstraZeneca PLC
• AbbVie Inc.
• Bayer AG

The detailed segments and sub-segment of the market are explained below:

By Drug Type
• Hypomethylating
• Immune Therapy
• Anti-anaemics

By Route of Administration
• Oral
• Parenteral

By Medication
• Branded
• Generic

By Cancer Type
• Refractory Anemia
• Refractory Cytopenia
• Others

By Age Group
• Pediatric
• Adult
• Geriatric

By End-user
• Hospitals
• Oncology Centers
• Specialty Clinics
• Homecare
• Others

By Region:

North America
• U.S.
• Canada

Europe
• UK
• Germany
• France
• Spain
• Italy
• Rest of Europe

Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• Rest of Asia Pacific

Latin America
• Brazil
• Mexico
• Rest of Latin America

Middle East & Africa
• Saudi Arabia
• South Africa
• Rest of Middle East & Africa

Years considered for the study are as follows:
• Historical year – 2022
• Base year – 2023
• Forecast period – 2024 to 2032

Key Takeaways:
• Market Estimates & Forecast for 10 years from 2022 to 2032.
• Annualized revenues and regional level analysis for each market segment.
• Detailed analysis of geographical landscape with country-level insights across key regions.
• Competitive landscape including major players with strategic initiatives.
• Analysis of key business strategies and forward-looking recommendations.
• Assessment of competitive structure within the industry.
• In-depth demand and supply chain analysis across the global MDS drugs ecosystem.



Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.

Table of Contents

285 Pages
Chapter 1. Global Myelodysplastic Syndrome Drugs Market Executive Summary
1.1. Global Myelodysplastic Syndrome Drugs Market Size & Forecast (2022–2032)
1.2. Regional Summary
1.3. Segmental Summary
1.3.1. By Drug Type
1.3.2. By Route of Administration
1.3.3. By Medication
1.3.4. By Cancer Type
1.3.5. By Age Group
1.3.6. By End user
1.4. Key Trends
1.5. Recession Impact
1.6. Analyst Recommendation & Conclusion
Chapter 2. Global Myelodysplastic Syndrome Drugs Market Definition and Research Assumptions
2.1. Research Objective
2.2. Market Definition
2.3. Research Assumptions
2.3.1. Inclusion & Exclusion
2.3.2. Limitations
2.3.3. Supply Side Analysis
2.3.3.1. Availability
2.3.3.2. Infrastructure
2.3.3.3. Regulatory Environment
2.3.3.4. Market Competition
2.3.3.5. Economic Viability (Payer & Patient Perspectives)
2.3.4. Demand Side Analysis
2.3.4.1. Improved Diagnostic Criteria & Early Detection
2.3.4.2. Technological Advancements in Drug Development
2.3.4.3. Patient Awareness & Support Programs
2.4. Estimation Methodology
2.5. Years Considered for the Study
Historical year – 2022
Base year – 2023
Forecast period – 2024 to 2032
2.6. Currency Conversion Rates
Chapter 3. Global Myelodysplastic Syndrome Drugs Market Dynamics
3.1. Market Drivers
3.1.1. Aging Population & Rising MDS Incidence
3.1.2. Launch of Novel Hypomethylating Agents & Immunotherapies
3.1.3. Shift Toward Oral Formulations & Biosimilars
3.2. Market Challenges
3.2.1. Treatment Resistance & Adverse Effects
3.2.2. High Cost of Branded Therapies & Access Barriers
3.2.3. Regulatory Complexities in Orphan Drug Approvals
3.3. Market Opportunities
3.3.1. Combination Therapy Development
3.3.2. NGS Based Patient Stratification
3.3.3. Low Intensity Regimens for Elderly/Frail Patients
Chapter 4. Global Myelodysplastic Syndrome Drugs Market Industry Analysis
4.1. Porter’s Five Forces Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.1.6. Futuristic Approach to Porter’s Model
4.1.7. Porter’s Impact Analysis
4.2. PESTEL Analysis
4.2.1. Political
4.2.2. Economic
4.2.3. Social
4.2.4. Technological
4.2.5. Environmental
4.2.6. Legal
4.3. Top Investment Opportunities
4.4. Top Winning Strategies
4.5. Disruptive Trends
4.6. Industry Expert Perspective
4.7. Analyst Recommendation & Conclusion
Chapter 5. Global Myelodysplastic Syndrome Drugs Market Size & Forecasts by Drug Type 2022–2032
5.1. Segment Dashboard
5.2. Global Market: Drug Type Revenue Trend Analysis, 2022 & 2032 (USD Billion)
5.2.1. Hypomethylating
5.2.2. Immune Therapy
5.2.3. Anti anaemics
Chapter 6. Global Myelodysplastic Syndrome Drugs Market Size & Forecasts by Route of Administration 2022–2032
6.1. Segment Dashboard
6.2. Global Market: Route of Administration Revenue Trend Analysis, 2022 & 2032 (USD Billion)
6.2.1. Oral
6.2.2. Parenteral
Chapter 7. Global Myelodysplastic Syndrome Drugs Market Size & Forecasts by Medication 2022–2032
7.1. Segment Dashboard
7.2. Global Market: Medication Revenue Trend Analysis, 2022 & 2032 (USD Billion)
7.2.1. Branded
7.2.2. Generic
Chapter 8. Global Myelodysplastic Syndrome Drugs Market Size & Forecasts by Cancer Type 2022–2032
8.1. Segment Dashboard
8.2. Global Market: Cancer Type Revenue Trend Analysis, 2022 & 2032 (USD Billion)
8.2.1. Refractory Anemia
8.2.2. Refractory Cytopenia
8.2.3. Others
Chapter 9. Global Myelodysplastic Syndrome Drugs Market Size & Forecasts by Age Group 2022–2032
9.1. Segment Dashboard
9.2. Global Market: Age Group Revenue Trend Analysis, 2022 & 2032 (USD Billion)
9.2.1. Pediatric
9.2.2. Adult
9.2.3. Geriatric
Chapter 10. Global Myelodysplastic Syndrome Drugs Market Size & Forecasts by End user 2022–2032
10.1. Segment Dashboard
10.2. Global Market: End user Revenue Trend Analysis, 2022 & 2032 (USD Billion)
10.2.1. Hospitals
10.2.2. Oncology Centers
10.2.3. Specialty Clinics
10.2.4. Homecare
10.2.5. Others
Chapter 11. Global Myelodysplastic Syndrome Drugs Market Size & Forecasts by Region 2022–2032
11.1. North America
11.1.1. U.S.
11.1.1.1. Drug Type breakdown, 2022–2032
11.1.1.2. Route of Administration breakdown, 2022–2032
11.1.2. Canada
11.2. Europe
11.2.1. UK
11.2.2. Germany
11.2.3. France
11.2.4. Spain
11.2.5. Italy
11.2.6. Rest of Europe
11.3. Asia Pacific
11.3.1. China
11.3.2. India
11.3.3. Japan
11.3.4. Australia
11.3.5. South Korea
11.3.6. Rest of Asia Pacific
11.4. Latin America
11.4.1. Brazil
11.4.2. Mexico
11.4.3. Rest of Latin America
11.5. Middle East & Africa
11.5.1. Saudi Arabia
11.5.2. South Africa
11.5.3. Rest of Middle East & Africa
Chapter 12. Competitive Intelligence
12.1. Key Company SWOT Analysis
12.1.1. Celgene Corporation (Bristol Myers Squibb)
12.1.2. Novartis AG
12.1.3. Otsuka Holdings Co., Ltd.
12.2. Top Market Strategies
12.3. Company Profiles
12.3.1. Celgene Corporation (Bristol Myers Squibb)
12.3.1.1. Key Information
12.3.1.2. Overview
12.3.1.3. Financial (Subject to Data Availability)
12.3.1.4. Product Summary
12.3.1.5. Market Strategies
12.3.2. Novartis AG
12.3.3. Otsuka Holdings Co., Ltd.
12.3.4. Takeda Pharmaceutical Company Limited
12.3.5. Pfizer Inc.
12.3.6. Johnson & Johnson
12.3.7. Merck & Co., Inc.
12.3.8. Sanofi S.A.
12.3.9. Teva Pharmaceutical Industries Ltd.
12.3.10. Amgen Inc.
12.3.11. F. Hoffmann La Roche Ltd
12.3.12. GlaxoSmithKline plc
12.3.13. AstraZeneca PLC
12.3.14. AbbVie Inc.
12.3.15. Bayer AG
Chapter 13. Research Process
13.1. Research Process
13.1.1. Data Mining
13.1.2. Analysis
13.1.3. Market Estimation
13.1.4. Validation
13.1.5. Publishing
13.2. Research Attributes
List of Tables
TABLE 1. Global Myelodysplastic Syndrome Drugs market, report scope
TABLE 2. Global MDS Drugs estimates & forecasts by Region 2022–2032 (USD Billion)
TABLE 3. Global estimates & forecasts by Drug Type 2022–2032 (USD Billion)
TABLE 4. Global estimates & forecasts by Route of Administration 2022–2032 (USD Billion)
TABLE 5. Global estimates & forecasts by Medication 2022–2032 (USD Billion)
TABLE 6. Global estimates & forecasts by Cancer Type 2022–2032 (USD Billion)
TABLE 7. Global estimates & forecasts by Age Group 2022–2032 (USD Billion)
TABLE 8. Global estimates & forecasts by End user 2022–2032 (USD Billion)
TABLE 9. North America estimates & forecasts 2022–2032 (USD Billion)
TABLE 10. U.S. estimates & forecasts by segment 2022–2032 (USD Billion)
TABLE 11. Canada estimates & forecasts by segment 2022–2032 (USD Billion)
TABLE 12. Europe estimates & forecasts 2022–2032 (USD Billion)
TABLE 13. UK estimates & forecasts by segment 2022–2032 (USD Billion)
TABLE 14. Germany estimates & forecasts by segment 2022–2032 (USD Billion)
TABLE 15. France estimates & forecasts by segment 2022–2032 (USD Billion)
TABLE 16. Asia Pacific estimates & forecasts 2022–2032 (USD Billion)
TABLE 17. Latin America estimates & forecasts 2022–2032 (USD Billion)
TABLE 18. Middle East & Africa estimates & forecasts 2022–2032 (USD Billion)
TABLE 19. Competitive landscape: company market share analysis (2023)
TABLE 20. SWOT summary of key companies
List of Figures
FIGURE 1. Global market research methodology
FIGURE 2. Market estimation techniques
FIGURE 3. Global market size estimates & forecast methods
FIGURE 4. Key market trends 2023
FIGURE 5. Growth prospects 2022–2032
FIGURE 6. Porter’s Five Forces model
FIGURE 7. PESTEL analysis
FIGURE 8. Value chain analysis
FIGURE 9. Drug Type segment share, 2023 vs. 2032
FIGURE 10. Route of Administration segment share, 2023 vs. 2032
FIGURE 11. Medication segment share, 2023 vs. 2032
FIGURE 12. Cancer Type segment share, 2023 vs. 2032
FIGURE 13. Age Group segment share, 2023 vs. 2032
FIGURE 14. End user segment share, 2023 vs. 2032
FIGURE 15. North America regional snapshot, 2023 vs. 2032
FIGURE 16. Europe regional snapshot, 2023 vs. 2032
FIGURE 17. Asia Pacific regional snapshot, 2023 vs. 2032
FIGURE 18. Latin America regional snapshot, 2023 vs. 2032
FIGURE 19. Middle East & Africa regional snapshot, 2023 vs. 2032
FIGURE 20. Company market share analysis (2023)

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us